BET Bromodomain Inhibition Enhances T Cell Persistence and Function in Adoptive Immunotherapy Models

Journal of Clinical Investigation - United States
doi 10.1172/jci86437
Full Text
Abstract

Available in full text

Categories
Medicine
Date
Authors
Publisher

American Society for Clinical Investigation

Related search

Inhibition of AKT Signaling Uncouples T Cell Differentiation From Expansion for Receptor-Engineered Adoptive Immunotherapy

JCI insight
Medicine
2017English

Synergistic Induction of Cell Death in Haematological Malignancies by Combined Phosphoinositide-3-Kinase and BET Bromodomain Inhibition

British Journal of Haematology
Hematology
2015English

The Emerging Role of in Vitro-Transcribed mRNA in Adoptive T Cell Immunotherapy

Molecular Therapy
Molecular MedicineMolecular BiologyPharmacologyMedicineGeneticsDrug Discovery
2019English

Adoptive T Cell Transfer for Cancer Immunotherapy in the Era of Synthetic Biology

Immunity
Infectious DiseasesAllergyImmunology
2013English

Enhanced Local and Systemic Anti-Melanoma CD8+ T Cell Responses After Memory T Cell-Based Adoptive Immunotherapy in Mice

Cancer Immunology, Immunotherapy
Cancer ResearchMedicineOncologyAllergyImmunology
2016English

Exploring Selective Inhibition of the First Bromodomain of the Human Bromodomain and Extra-Terminal Domain (BET) Proteins

English

Systemic Adoptive T-Cell Immunotherapy in Recurrent and Metastatic Carcinoma of the Head and Neck

Archives of Otolaryngology–Head & Neck Surgery
2000English

Failed Adoptive Immunotherapy With Tumor-Specific T Cells

Cancer Research
Cancer ResearchOncology
2004English

Adoptive Immunotherapy of Cancer Using CD4+ T Cells

Current Opinion in Immunology
AllergyImmunology
2009English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy